Methods |
For characteristics see Fundamental 2014a1
|
Participants |
|
Interventions |
|
Outcomes |
|
Notes |
|
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not reported |
Allocation concealment (selection bias) |
Unclear risk |
Not reported |
Blinding of participants and personnel (performance bias) All outcomes |
Low risk |
Double‐blind |
Blinding of outcome assessment (detection bias) All outcomes |
Unclear risk |
Not reported |
Incomplete outcome data (attrition bias) All outcomes |
Low risk |
There was only missing data for 2 participants |
Selective reporting (reporting bias) |
High risk |
The secondary outcomes were changed from the original secondary outcomes |
Vested‐interest bias |
High risk |
The study was funded by Novartis |
Other bias |
Low risk |
The trial appeared to be free of other components that could put it at risk of bias |